ANZCTR search results

The study is interventional, employing behavioural approaches and diagnostic procedures. The behavioural change aims to instil during the day (awake) and continue abdominal breathing by the participants during sleep. The study will include instructions, training and bringing abdominal muscle awareness to participants during breathing which will be mirrored with biofeedback. Secondly diagnostic procedure via Polysomnographic (PSG) sleep studies will authenticate definitive outcomes. The training on the interventions will be delivered by staff trained by Dr Peter Keller and Ms Thanusha Sothiratnam with 26 years and 14 years of experience respectively in the field of sleep diagnosis and treatment. The mode of delivery will be face to face preferably in group sessions (individually if requested by participants), employing instructions, training, as well as remote monitoring via telephone and internet.

This study concerns the development and testing of a mobile phone application for the audio recording of oncology consultations. Who is it for? You may be eligible for this study if you are a cancer consumer or staff member at the Peter MacCallum Cancer Centre. Study details You may be invited to try a new consultation audio-recording app during your next consultation at Peter MacCallum Cancer Centre. An ‘app’ is a program that you can use on a mobile phone or tablet device. Patients who decide to take part, will be asked to audio-record their next consultation using the app. A copy of the audio-recording will also be kept and securely stored at Peter Mac. For those patients who decide to take part, any family members or friends who accompany them to your hospital consultation will be asked whether they are happy to be audio-recorded by the app during the consultation. . People who decide to take part in this study will be contacted one week after their audio-recorded consultation to complete in a telephone survey (30 minutes) to discuss what they think about the audio-recording app. We will audio-record this interview so that we can listen back over your answers and combine them with everyone else’s to get our results. The audio-recording of the telephone interview will be stored for 5 years post study completion. There are no costs associated with participating in this research project, nor will you be paid. It is hoped this research will contribute to the implementation of the audio recording app at Peter Mac. Oncology consultations contain a lot of information, and patients and their family members/friends may be very anxious while at the hospital, which makes it hard to remember everything that is discussed in the consultation. We hope that having an easy to use audio-recording app will be helpful for patients and their family members/friends by allowing them to re-listen to the consultation at their convenience. We have designed this app with help from people like you, and now we would like to try using the app in a health care setting. We are looking at how best to use the app in the hospital, and so we are seeking feedback from patients and health care professionals.

The primary aim of this study is to investigate if providing three short 15 minute sessions of physiotherapy each therapy day for patients admitted to inpatient rehabilitation after hip fracture is more effective than providing the usual one long 45 minute session each therapy day in improving mobility. The secondary aims of this study are to: * Determine if this model of care reduces length of stay in this patient group * Determine whether more walking is achieved in 3 shorter sessions 5 days/week versus 1 longer session 5 days/week both within and outside of therapy sessions * Determine whether there is an increased chance of returning home with this model of care * Determine if Functional Independence Measure Scores for mobility improve faster in the distributed model * Compare the 30 day readmission rate after discharge in both groups * Determine if the new model of care is acceptable to patients and physiotherapists by means of a brief survey about the project.

The aim of this 15-year follow-up study was to determine the influence of environmental, anatomical, metabolic, physiological and genetic determinants on health outcomes in older women. This was a follow-up study of 1500 women aged 70 years and over, recruited from the general population of Perth, Western Australia.

What is this study for? This study aims to assess the psychological and behavioral outcomes associated with offering women their personal polygenic risk score for breast cancer risk. The study will include women who opt to receive their results as well, as those who decline this offer. Who is it for? You may be eligible to participate in this trial if you are a woman aged 18 or over who has already enrolled in the 'Variants in Practice’ study (ViP) in whom known breast cancer predisposition genes have been excluded as the cause of your personal and/or familial breast cancer risk. Study details: Participants enrolled in this trial will have a personal polygenic risk score (PRS). Individual PRS result has been calculated as part of the parent study “Variants in Practice”. Participants who opt to receive the results will then attend a one hour face-to-face session with a clinical geneticist or genetic counsellor who has received training in delivering these results. During this session, the risk score will be discussed as well as any preventative strategies which may be considered. Participants can also opt to not receive their results, in which case they will not receive this face-to-face session. All participants will be asked to complete a number of questionnaires assessing the psychological effects of receiving or not receiving their risk score. It is hoped that the findings from this trial will help to develop a model of care offering polygenic breast cancer risk testing, in which results are provided to participants without causing negative psychological effects such as breast cancer anxiety and depression.

The aim of this research project is to test the preliminary feasibility, effectiveness and possible mechanisms of change of a CPT-C treatment program that is tailored to incorporate cultural differences in self-concept and trauma related appraisals for use among South East Asian trauma survivors. The primary aim of the research project is to (1) determine the efficacy of a group culturally-modified CPT (cm-CPT) protocol for the treatment of individuals from a South East Asian Background with moderate-high levels of PTSD symptomatology (2) assess feasibility, treatment adherence and client satisfaction of cm-CPT (3) examine moderators, mediators, and mechanisms of change.

The purpose of this study is to further explore the effect of colloidal silver sinonasal rinses in recalcitrant chronic rhinosinusitis. Colloidal silver has already shown to be effective as an anti-biofilm agent in Staphylococcus aureus chronic rhinosinusitis (CRS) in a sheep model (Rajiv et al, 2015). We aim to further evaluate the effects of colloidal silver in patients affected by recalcitrant CRS. The specific aim of this study is to investigate the effect of colloidal silver on persistent infection in patients who have already undergone surgical management for chronic rhinosinusitis (CRS).

Following emergence from coma individuals with traumatic brain injury (TBI) experience a period of confusion, amnesia, and sometimes agitation, termed post-traumatic amnesia (PTA). Guidelines for management of patients in PTA have traditionally recommended that these patients not receive active therapy during this phase. However, this management strategy has never been empirically tested and anecdotal evidence implicates potential benefits from rehabilitation during PTA. Retraining of daily living skills such as personal care activities (e.g., dressing) and domestic tasks (e.g., meal preparation), known as activities of daily living (ADLs), is a core focus of the rehabilitation program in the post-PTA phase. Efficacy of commencing ADL retraining during the PTA phase has never been systematically assessed. The proposed randomised controlled trial is designed to evaluate the efficacy of commencing ADL retraining during the PTA phase after severe TBI (treatment group), as compared to introducing ADL retraining after emergence from PTA (treatment as usual control group).

This study aims to implement and evaluate the feasibility of an integrated care model for prostate cancer patients that incorporates both local and centralised services. You may be eligible to join this study if you are aged 18 years or above and have been diagnosed with localised prostate cancer within the previous 3 months, OR diagnosed with advanced prostate cancer for at least 12 months. All patients in this study will be provided with local and centralised prostate cancer support services. These include Care Coordination, Information Provision and Decision Support, Practical Support, Peer Support, Lifestyle Plan, Speialised Support Services, and Advanced Prostate Cancer Comorbidities Management. While each component of the intervention is available for all participants, the intervention and each of its components are tailored to the patient’s stage of disease and their health related needs. Delivery of specialised support services will depend on resource availabililty, access, treating specialist /team preference and preference of the patient. Patients in this study will be asked to complete 3 surveys over a 6 month period (at the commencement of participation, followed by 3 and 6 months after the commencement of participation) in order to assess their quality of life, prostate cancer symptoms and mental health. In addition, service and carer-related outcomes will be measured. At 6 months after the commencement of participation, patients, carers and key personnel involved in delivering the intervention will be invited to complete an online survey and participate in individual interviews. This is a pilot study focused on determining feasiblity of a larger randomised study. If the intervention is effective, men with prostate cancer will have access to evidence based supportive care interventions that will contributed to improved health outcomes and quality of life.

The study is comparing two different techniques to diagnose acute pulmonary embolism in patients referred to the Peter MacCallum Cancer Institute. Who is it for? You may be eligible to join this study if you are aged 18 years or above and have been referred to the Peter MacCallum Cancer Institute for suspicion of acute pulmonary embolism. What is the purpose of this research? Lung scan (also known as lung scintigraphy, ventilation/perfusion scan or V/Q scan) and CT pulmonary angiogram (called CTPA) are imaging tests that are used to diagnose pulmonary embolism (clots in the blood vessels supplying the lungs). This research project is assessing the diagnostic value of a new imaging test called lung PET/CT. PET/CT stands for Positron Emission Tomography/Computed Tomography. The conventional lung scan uses a different technology called SPECT/CT (Single Photon Emission Tomography/Computed Tomography). PET/CT produces images of better quality than the conventional SPECT/CT scan, which may improve diagnosis of pulmonary embolism. The research project is designed to compare the diagnostic value of lung PET/CT and CTPA for the diagnosis of pulmonary embolism. Our hypotheses are that V/Q PET/CT is an alternative modality to CTPA for diagnosis of PE and that the combination of both imaging may improve PE diagnosis. What does participation in this research involve? You will undergo both CTPA and lung PET/CT scans. For the lung PET/CT scan, a small quantity of a substance called Galligas, which are particles labelled with a radioactive substance called Ga-68, is breathed in and thereby deposited into your lungs. After this, you will be required to lay still on the PET/CT camera bed for about 10 minutes whilst images are obtained. Whilst you are in the PET/CT scanner, you are then injected with a substance called Ga-MAA via the intravenous catheter. Ga-MAA stands for Ga-68 macroaggregated albumin (MAA) and is radioactive substance that localises in your lungs’ blood vessels. You will then be imaged again for a further 10 minutes. Lung PET/CT is a diagnostic procedure only, not a treatment. Lung PET/CT and CTPA will be initially interpreted separately. CTPA and V/Q PET/CT images will then be interpreted together by a consensus reading. It is anticipated that 50 patients will participate in this project.